JP7712919B2 - マルチドメインタンパク質ワクチン - Google Patents

マルチドメインタンパク質ワクチン

Info

Publication number
JP7712919B2
JP7712919B2 JP2022521651A JP2022521651A JP7712919B2 JP 7712919 B2 JP7712919 B2 JP 7712919B2 JP 2022521651 A JP2022521651 A JP 2022521651A JP 2022521651 A JP2022521651 A JP 2022521651A JP 7712919 B2 JP7712919 B2 JP 7712919B2
Authority
JP
Japan
Prior art keywords
polypeptide
sequence
peptide
antigen
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022521651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551918A (ja
JP2022551918A5 (enExample
Inventor
エドワード フリッチュ，
ドミニク バーセルミ，
コーディー ホワイト，
リンリン ジャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2022551918A publication Critical patent/JP2022551918A/ja
Publication of JP2022551918A5 publication Critical patent/JP2022551918A5/ja
Priority to JP2025117198A priority Critical patent/JP2025148481A/ja
Application granted granted Critical
Publication of JP7712919B2 publication Critical patent/JP7712919B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022521651A 2019-10-09 2020-10-08 マルチドメインタンパク質ワクチン Active JP7712919B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025117198A JP2025148481A (ja) 2019-10-09 2025-07-11 マルチドメインタンパク質ワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962912903P 2019-10-09 2019-10-09
US62/912,903 2019-10-09
PCT/US2020/054785 WO2021072075A1 (en) 2019-10-09 2020-10-08 Multi-domain protein vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025117198A Division JP2025148481A (ja) 2019-10-09 2025-07-11 マルチドメインタンパク質ワクチン

Publications (3)

Publication Number Publication Date
JP2022551918A JP2022551918A (ja) 2022-12-14
JP2022551918A5 JP2022551918A5 (enExample) 2023-10-17
JP7712919B2 true JP7712919B2 (ja) 2025-07-24

Family

ID=75437582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521651A Active JP7712919B2 (ja) 2019-10-09 2020-10-08 マルチドメインタンパク質ワクチン
JP2025117198A Pending JP2025148481A (ja) 2019-10-09 2025-07-11 マルチドメインタンパク質ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025117198A Pending JP2025148481A (ja) 2019-10-09 2025-07-11 マルチドメインタンパク質ワクチン

Country Status (8)

Country Link
US (1) US20240317830A1 (enExample)
EP (1) EP4041295A4 (enExample)
JP (2) JP7712919B2 (enExample)
KR (1) KR20220110181A (enExample)
CN (1) CN114929264A (enExample)
AU (1) AU2020361515A1 (enExample)
CA (1) CA3156704A1 (enExample)
WO (1) WO2021072075A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023034901A1 (en) 2021-09-01 2023-03-09 The Broad Institute, Inc. Tumor avatar vaccine compositions and uses thereof
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
EP4522754A1 (en) * 2022-05-12 2025-03-19 Sunvax MRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
KR20240017325A (ko) * 2022-07-29 2024-02-07 주식회사 엘지화학 항원 전달용 재조합 융합 단백질 및 이의 이용
CN122497685A (zh) * 2024-01-05 2026-07-31 安捷伦科技有限公司 通过表位调谐控制多克隆体液反应中的抗体特异性

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075392A1 (en) 2005-07-19 2009-03-19 John Colyer Agents for and method of quanitifying multiple related components in a biological system
WO2018135651A1 (ja) 2017-01-20 2018-07-26 国立大学法人埼玉大学 抗体－多糖結合体及びそれを用いた高感度免疫測定方法
WO2019008335A1 (en) 2017-07-07 2019-01-10 Avacta Life Sciences Limited SCAFFOLD PROTEINS
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319828A1 (en) * 1998-01-29 1999-08-05 Miller, Samuel High density arrays for proteome analysis and methods and compositions therefor
CA2334946A1 (en) * 1998-08-17 2000-02-24 Phylos, Inc. Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular rna-protein fusion formation
EP1603590A4 (en) * 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
GB0807065D0 (en) * 2008-04-18 2008-05-21 Univ Leeds Novel scaffolds
US12049667B2 (en) * 2017-05-26 2024-07-30 Abvitro Llc High-throughput polynucleotide library sequencing and transcriptome analysis
IL277128B2 (en) * 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075392A1 (en) 2005-07-19 2009-03-19 John Colyer Agents for and method of quanitifying multiple related components in a biological system
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
WO2018135651A1 (ja) 2017-01-20 2018-07-26 国立大学法人埼玉大学 抗体－多糖結合体及びそれを用いた高感度免疫測定方法
WO2019008335A1 (en) 2017-07-07 2019-01-10 Avacta Life Sciences Limited SCAFFOLD PROTEINS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Aurisicchio, L. et al.，"A novel minigene scaffold for therapeutic cancer vaccines"，Oncoimmunology，2014年，Vol. 3: e27529，pp. 1-13
Estrada, S. et al.，"The role of Gly-4 of human cystatin A (stefin A) in the binding of target proteinases. Characterization by kinetic and equilibrium methods of the interactions of cystatin A Gly-4 mutants with papain, cathepsin B, and cathepsin L"，Biochemistry，1998年，Vol. 37，pp. 7551-7560

Also Published As

Publication number Publication date
KR20220110181A (ko) 2022-08-05
WO2021072075A1 (en) 2021-04-15
CN114929264A (zh) 2022-08-19
AU2020361515A1 (en) 2022-05-26
JP2025148481A (ja) 2025-10-07
JP2022551918A (ja) 2022-12-14
EP4041295A4 (en) 2024-04-10
EP4041295A1 (en) 2022-08-17
CA3156704A1 (en) 2021-04-15
US20240317830A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
JP7762750B2 (ja) ネオ抗原およびその使用
JP7491965B2 (ja) ネオ抗原およびその使用方法
JP7754971B2 (ja) ネオ抗原およびそれらの使用
US20240100139A1 (en) Neoantigens and uses thereof
JP2025148481A (ja) マルチドメインタンパク質ワクチン
JP2024535855A (ja) Ｋｒａｓネオ抗原療法
RU2805196C2 (ru) Неоантигены и их применение
RU2813924C2 (ru) Неоантигены и их применение
HK40050847A (en) Neoantigens and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250613

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250711

R150 Certificate of patent or registration of utility model

Ref document number: 7712919

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150